Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 705 free, full-text research articles on human participants. First 3 results:

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
 

Author(s): Li Ye, Yanling Ren, Xinping Zhou, Chen Mei, Liya Ma, Xingnong Ye, Juying Wei, Weilai Xu, Haitao Meng, Wenbin Qian, Wenyuan Mai, Yinjun Lou, Gaixiang Xu, Jiejing Qian, Yejiang Lou, Yingwan Luo, Lili Xie, Peipei Lin, Chao Hu, Jie Jin, Hongyan Tong

Journal: J. Cancer Res. Clin. Oncol.. 2017 May;143(5):873-882.

 

The aim of this study was to examine whether decitabine priming prior to low-dose chemotherapeutic regimens could improve outcomes in patients with myelodysplastic syndromes-refractory anemia with excess of blasts (MDS-RAEB).

Last Updated: 21 Jan 2017

Go To URL
Relevance of prognostic factors in the decision-making of stem cell transplantation in Myelodysplastic Syndromes.
 

Author(s): Fernando Barroso Duarte, Talyta Ellen de Jesus Dos Santos, Maritza Cavalcante Barbosa, Jacques Kaufman, João Paulo de Vasconcelos, Romélia Pinheiro Gonçalves Lemes, Francisco Dário Rocha, Diego Ferreira Coutinho, Ilana Zalcberg, Paulo Roberto Leitão de Vasconcelos

Journal: Rev Assoc Med Bras (1992). 2016 Oct;62 Suppl 1():25-28.

 

The hematopoietic stem cell transplantation (HSCT) is the only curative alternative for Myelodysplastic Syndrome (MDS), but many patients are not eligible for this treatment, as there are several limiting factors, especially in the case of patients with low-risk MDS. The aim of this ...

Last Updated: 16 Dec 2016

Go To URL
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
 

Author(s): John S Welch, Allegra A Petti, Christopher A Miller, Catrina C Fronick, Michelle O'Laughlin, Robert S Fulton, Richard K Wilson, Jack D Baty, Eric J Duncavage, Bevan Tandon, Yi-Shan Lee, Lukas D Wartman, Geoffrey L Uy, Armin Ghobadi, Michael H Tomasson, Iskra Pusic, Rizwan Romee, Todd A Fehniger, Keith E Stockerl-Goldstein, Ravi Vij, Stephen T Oh, Camille N Abboud, Amanda F Cashen, Mark A Schroeder, Meagan A Jacoby, Sharon E Heath, Kierstin Luber, Megan R Janke, Andrew Hantel, Niloufer Khan, Madina J Sukhanova, Randall W Knoebel, Wendy Stock, Timothy A Graubert, Matthew J Walter, Peter Westervelt, Daniel C Link, John F DiPersio, Timothy J Ley

Journal: N. Engl. J. Med.. 2016 11;375(21):2023-2036.

 

The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear.

Last Updated: 13 Dec 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 143 free, full-text review articles on human participants. First 3 results:

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
 

Author(s): Antonio Almeida, Pierre Fenaux, Alan F List, Azra Raza, Uwe Platzbecker, Valeria Santini

Journal: Leuk. Res.. 2017 Jan;52():50-57.

 

Patients with lower-risk myelodysplastic syndromes (MDS) are affected primarily by symptoms of chronic anemia and fatigue rather than progression to acute myeloid leukemia. Severe thrombocytopenia, although less common in lower-risk MDS, is associated with increased risk of bleeding. ...

Last Updated: 24 Nov 2016

Go To URL
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
 

Author(s): Rami S Komrokji

Journal: Am Soc Clin Oncol Educ Book. 2016 ;35():e345-52.

 

Hypomethylating agents (HMAs) are the mainstay treatment of patients with myelodysplastic syndromes. Hypomethylating agents remain the only treatment, other than allogeneic hematopoietic stem cell transplantation (AHSCT), that improves overall survival (OS) for patients with higher-risk ...

Last Updated: 2 Jun 2016

Go To URL
Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes.
 

Author(s): Gregory A Abel, Rena Buckstein

Journal: Am Soc Clin Oncol Educ Book. 2016 ;35():e337-44.

 

Myelodysplastic syndromes (MDS) are a group of acquired hematopoietic stem cell disorders that manifest with progressive bone marrow failure and have a propensity to transform into leukemia. Although an increase in biologic understanding of MDS has led to improved patient risk stratification ...

Last Updated: 2 Jun 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of DSP-7888 in Patients With Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Myelodysplastic Syndrome

 

Last Updated: 1 Mar 2017

Go to URL
Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)
 

Status: Not yet recruiting

Condition Summary: Myelodysplastic Syndromes

 

Last Updated: 12 Jun 2017

Go to URL
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Myelodysplastic Syndrome

 

Last Updated: 9 Mar 2017

Go to URL